MBX Biosciences MBX 深 沪
等待开盘 07-23 09:30:00 美东时间
12.07
-0.120
-0.98%
华盛通- 最 高12.66
- 今 开12.22
- 成交量 13.61万股
- 最 低 11.91
- 昨 收 12.19
- 总市值 4.03亿
- 52周最高 27.50
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 4.8069
- 委 比 20.00%
- 总股本 3342.44万
- 历史最高 27.50
- 量 比 0.57
- 振 幅 6.15%
- 历史最低 4.8069
- 每 手 1
- 风险率 5.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Mainz Biomed N.V. has received public funding from the German Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer project. The state will fund up to 50% of the project’s costs, supporting the company’s non-invasive blood-based screening test for early pancreatic cancer detection. The grant emphasizes the project’s medical and technological relevance, aiming to bridge a critical gap in cancer diagnostics by enabling earl...
06-25 12:01
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.
06-25 02:59
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
MBX Biosciences appoints Dr. Andreas Moraitis as Senior Vice President of Clinical Development. Dr. Moraitis, an experienced endocrinologist, will lead the clinical development of canvuparatide, a potential treatment for hypoparathyroidism. His expertise in endocrinology and track record in clinical development programs will support MBX's pipeline of therapies for endocrine and metabolic disorders.
06-23 12:00
MBX Biosciences Submits IND for Obesity Treatment
MBX Biosciences, Inc. ( ($MBX) ) has provided an announcement. On June 16, 2025...
06-16 20:29
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
MBX Biosciences submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist for obesity treatment. Designed using the company's PEP™ platform, MBX 4291 aims to offer once-monthly dosing, improved gastrointestinal tolerability, and enhanced weight loss. A Phase 1 trial in healthy overweight volunteers is expected to begin in Q3 2025. The investigational drug, with extended duration compared to tirzepatide, hig...
06-16 12:00
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
MBX Biosciences will present two posters on MBX 1416, a GLP-1 receptor antagonist, at the American Diabetes Association’s 85th Scientific Sessions. These posters will highlight Phase 1 safety, pharmacokinetics, and pharmacodynamics in healthy volunteers, as well as its ability to elevate blood glucose in rats without altering body weight. MBX 1416 is being developed as a potential once-weekly treatment for post-bariatric hypoglycemia, a serious a...
06-10 12:00
MBX Biosciences Updates Corporate Presentation June 2025
The latest announcement is out from MBX Biosciences, Inc. ( ($MBX) ). On June 9...
06-09 20:20
MBX Biosciences to Participate in June Investor Conferences
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: M...
05-20 20:00
MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from
05-12 21:32
MBX Biosciences GAAP EPS of -$0.71
MBX Biosciences press release (NASDAQ:MBX): Q1 GAAP EPS of -$0.71. Cash and Cash Equivalents and Marketable Securities: As of March 31, 2025, MBX Biosciences had cash, cash equivalents and marketable ...
05-12 20:55
